Insider Selling: Medpace (NASDAQ:MEDP) CEO Sells $6,749,952.00 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 10,880 shares of the company’s stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $620.40, for a total transaction of $6,749,952.00. Following the completion of the transaction, the chief executive officer owned 504,273 shares of the company’s stock, valued at $312,850,969.20. This trade represents a 2.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Medpace Stock Up 1.9%

Shares of NASDAQ MEDP traded up $11.87 during midday trading on Monday, hitting $624.20. The stock had a trading volume of 184,242 shares, compared to its average volume of 333,585. The business’s 50 day moving average is $585.86 and its 200-day moving average is $510.89. The company has a market cap of $17.42 billion, a P/E ratio of 36.59, a PEG ratio of 2.73 and a beta of 1.15. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm’s revenue was up 17.2% on a year-over-year basis. During the same quarter last year, the business posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Institutional Investors Weigh In On Medpace

Hedge funds have recently bought and sold shares of the business. Johnson Financial Group Inc. bought a new stake in shares of Medpace during the 2nd quarter valued at $27,000. Jones Financial Companies Lllp purchased a new stake in Medpace during the 2nd quarter valued at about $30,000. Allied Private Wealth LLC acquired a new position in shares of Medpace in the second quarter worth about $31,000. Kilter Group LLC purchased a new stake in shares of Medpace during the second quarter worth $31,000. Finally, Basecamp Wealth Advisors LLC lifted its stake in shares of Medpace by 187.5% in the 1st quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock valued at $33,000 after purchasing an additional 45 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

MEDP has been the subject of a number of recent research reports. Jefferies Financial Group reiterated a “hold” rating on shares of Medpace in a report on Monday, September 14th. Weiss Ratings upgraded shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. Mizuho boosted their price target on Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Robert W. Baird boosted their price objective on Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a report on Friday, July 24th. Finally, Royal Bank Of Canada increased their price objective on shares of Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Three analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $595.20.

Medpace Company Profile

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.